China Pharma Holdings, Inc. (the “Company”) received a notice from the Securities and Exchange Commission (“SEC”) on December 22, 2016 informing the Company that the Public Company Accounting Oversight Board (“PCAOB”) had revoked the registration of the Company’s prior auditor, Arshak Davtyan, Inc.. The Company was informed that the prior auditor was no longer registered with the PCAOB, and that the Company may not include any audit reports or consents in its filings with the SEC from the prior auditor on or after the date of deregistration.

About CHINA PHARMA HOLDINGS, INC. (NYSEMKT:CPHI)

China Pharma Holdings, Inc. is a holding company. The Company conducts its production, marketing, finance, development and administrative activities through its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson) in the People’s Republic of China (PRC). It is engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with various diseases and medical conditions in the PRC. It manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, oral solutions and granules. Its pharmaceutical products are sold on a prescription basis and are approved by the China Food and Drug Administration (the CFDA). The Company manufactured over 20 pharmaceutical products for various diseases and medical indications. It offers products for Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases and Others.

CHINA PHARMA HOLDINGS, INC. (NYSEMKT:CPHI) Recent Trading Information

CHINA PHARMA HOLDINGS, INC. (NYSEMKT:CPHI) closed its last trading session up +0.007 at 0.247 with 16,616 shares trading hands.